A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

Summary

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Timeline

Start

2025-06-03

Primary completion

2026-12-17

Completion

2029-10-17

Drugs

Indications